Skip to main content
Clinical Trials/EUCTR2017-004929-33-AT
EUCTR2017-004929-33-AT
Active, not recruiting
Phase 1

Effect of Ciclosporin eyedrops on ocular symptoms and optical image quality in patients with primary or secondary Sjögren syndrome

KH Hietzing, Department of Ophthalmology0 sites20 target enrollmentNovember 27, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
primary or secondary Sjögren Syndrome
Sponsor
KH Hietzing, Department of Ophthalmology
Enrollment
20
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 27, 2018
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
KH Hietzing, Department of Ophthalmology

Eligibility Criteria

Inclusion Criteria

  • \- Diagnosis of severe keratoconjunctivitis sicca defined by:
  • 1\) Staining of the cornea \= Grade III according to the Oxford scale
  • 2\) OSDI value \= 12
  • \- Age between 18 and 90 years
  • \- Primary or secondary Sjögren syndrome (defined according to the American\-European Consensus Group criteria)
  • \- Stable course of the underlying rheumatic disease and unchanged systemic treatment for 6 months
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 15

Exclusion Criteria

  • \- Pregnancy
  • \- Children and adolescents up to the age of 18
  • \- Eye surgery in the last 6 months
  • \- Simultaneous participation in another study
  • \- Regular use of eye drops except for tear substitutes
  • \- Use of Ciclosporin\-containing or Corticosteroid\-containing eye drops in the last 6 months

Outcomes

Primary Outcomes

Not specified

Similar Trials